What is Sientra?
Founded in 2003 and headquartered in Goleta, California, Sientra operates at the intersection of medical technology and aesthetic surgery. The company specializes in the development and commercialization of high-quality silicone gel breast implants, catering to the specific needs of plastic surgeons and their patients. By focusing on rigorous clinical standards and innovative product design, Sientra has established itself as a trusted partner for medical professionals seeking reliable aesthetic solutions. Its market position is defined by a commitment to safety, efficacy, and long-term patient outcomes, which has been instrumental in securing its reputation within the highly regulated medical aesthetics industry.
How much funding has Sientra raised?
Sientra has raised a total of $597M across 9 funding rounds:
Series C
$65M
Stock Offering
$80.2M
Stock Offering
$66M
Debt
$20M
Stock Offering
$107.7M
Stock Offering
$108.1M
Debt
$60M
Debt
$5M
Series C (2012): $65M led by Abingworth, Clarus Ventures, and OrbiMed
Stock Issuance/Offering (2014): $80.2M, investors not publicly disclosed
Stock Issuance/Offering (2015): $66M, investors not publicly disclosed
Debt (2017): $20M backed by Silicon Valley Bank
Stock Issuance/Offering (2018): $107.7M, investors not publicly disclosed
Stock Issuance/Offering (2019): $108.1M, investors not publicly disclosed
Debt (2020): $60M supported by Deerfield Communications Inc
Debt (2020): $5M featuring PPP
Key Investors in Sientra
Abingworth
Abingworth is a leading transatlantic life sciences investment firm that transforms cutting-edge science into novel medicines by providing capital and expertise to top-tier management teams.
Clarus Ventures
Blackstone Life Sciences, formerly Clarus Ventures, focuses on bringing vital medicines and technologies to market by addressing the funding gap in the life sciences sector through late-stage development investments.
OrbiMed
OrbiMed Advisors LLC is a specialized healthcare investment firm that manages capital across biopharmaceuticals, medical devices, and digital health, supporting companies from early-stage ventures to established organizations.
What's next for Sientra?
Looking ahead, Sientra is well-positioned to leverage its historical capital influx to drive further innovation and market penetration. The strategic deployment of $5M suggests a focus on strengthening the company's balance sheet and supporting its core commercial activities. As the medical aesthetics market continues to evolve, Sientra's ability to integrate clinical expertise with robust financial planning will be critical. Future growth initiatives are likely to center on expanding its product portfolio, enhancing distribution channels, and maintaining the high standards of quality that have defined its brand since inception. The company remains a key entity to watch as it navigates the complexities of the global healthcare market, utilizing its established investor relationships to fuel sustainable long-term value creation.
See full Sientra company page
